It is noteworthy that ANXA1 shows differences in expression levels in the highly heterogeneous breast cancer: Patients with luminal breast cancer showed loss of ANXA1 expression, whereas patients with BRCA1/2 mutation, triple-negative, and poorly differentiated breast cancer showed ANXA1 upregulation (9). This evidence concerns the gene BRCA1 and breast carcinoma.